Infusional Mitoxantrone Plus Bolus Melphalan as a Stem Cell Transplant Conditioning Regimen for Multiple Myeloma

REFERENCES

• Hoogstraten B, Sheehe PR, Cuttner J, Cooper T, Kyle RA, Oberfield RA, Townsend SR, Harley JB, Hayes DM, Costa G, Holland JF. Melphalan in multiple myeloma. Blood 1967;30(1):74–83.
   PubMed Web of Science ®Google Scholar
• Salmon S, Haut A, Bonnet JD, Amare M, Weick JK, Durie BG, Dixon DO. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1983;1:453–461.
   PubMed Web of Science ®Google Scholar
• MacLennan IC, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet 1992;339(8787):200–205.
   PubMed Web of Science ®Google Scholar
• Durie BG, Dixon DO, Carter S, Stephens R, Rivkin S, Bonnet J, Salmon SE, Dabich L, Files JC, Costanzi JJ. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1986;4(8):1227–1237.
   PubMed Web of Science ®Google Scholar
• Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10(2):334–342.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T, Selby P, Treleavan J, Viner C, Malpas J. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994;12(4):759–763.
   PubMed Web of Science ®Google Scholar
• Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23(36):9227–9233.
   PubMed Web of Science ®Google Scholar
• Attal M, Huguet F, Schlaifer D, Payen C, Laroche M, Fournie B, Mazieres B, Pris J, Laurent G. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992;79(5): 1130–1136.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisoneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335(2):91–97.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Kalish LA, Kyle RA, Hahn RG, Tormey DC, Oken MM. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1995;18(6):475–480.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Zhuang SH, Parekh T, Xiu L, Harousseau JL. The combination of pegylated liposomal doxorubicin and bortexomib significantly improves time to progression of patients with relapsed/refractory multiple myeloma compared with bortezomib alone: results from a planned interim analysis of a randomized phase III study (Abstract). In 48th American Society of Hematology Proceedings; Orlando 2006 December, 404.
   Google Scholar
• Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BC, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005;105(8):3058–3065.
   PubMed Web of Science ®Google Scholar
• Phillips JK, Sherlaw-Johnson C, Pearce R, Davies JM, Reilly JT, Newland AC, Cawley JC. A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. Leuk Lymphoma 1995;17(5-6):465–472.
   PubMed Web of Science ®Google Scholar
• Phillips JK. Resistant multiple myeloma treated with mitozantrone in combination with vincristine and dexamethasone (MOD). Eur J Haematol 1989;42(1):109–110.
   PubMed Web of Science ®Google Scholar
• Samson D, Gaminara E, Newland A, Van de Pette J, Kearney J, McCarthy D, Joyner M, Aston L, Mitchell T, Hamon M, Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989;2(8668):882–885.
   PubMed Web of Science ®Google Scholar
• Sprague K, Padgaonkar V, Klein AK, Chan GW, Miller KB, Klingemann H. Mitoxantrone and melphalan conditioning regimen for autologous peripheral blood stem cell transplantation in adults with acute myelogenous leukemia (Abstract). In ASH Annual Meeting; 2005, 5512.
   Google Scholar
• Ballestrero A, Ferrando F, Miglino M, Clavio R, Gonella R, Garuti R, Grasso R, Ghio R, Balleari E, Gobbi M, Patrone F. Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma. Eur J Haematol 2002;68(2):101–106.
   PubMed Web of Science ®Google Scholar
• Farjami S, Akhtar A, Kancherla RM, Liu D, Deiter K, Ahmed T. Progressively intensified chemotherapy: A phase II trial in patients with multiple myeloma (Abstract). In ASH Annual Meeting 2004, 4951.
   Google Scholar
• Mulder PO, Sleijfer DT, Willemse PH, de Vries EG, Uges DR, Mulder NH. High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer Res 1989;49(16):4654–4658.
   PubMed Web of Science ®Google Scholar
• Schenkein DP, Roitman D, Miller KB, Morelli J, Stadtmauer E, Pecora AL, Cassileth P, Fernandez H, Cooper BW, Kutteh L, Lazarus HM. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1997;3(4):210–216.
   PubMedGoogle Scholar
• Vogelzang NJ. Continuous infusion chemotherapy: a critical review. J Clin Oncol 1984;2(11):1289–1304.
   PubMed Web of Science ®Google Scholar
• Kaminer LS, Choi KE, Daley KM, Larson RA. Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia. Cancer 1990;65(12):2619–2623.
   PubMed Web of Science ®Google Scholar
• Koc Y, Oyan B, Kars A, Tekuzman G, Canpinar H, Kansu E. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia. Hematol Oncol 2004;22(2): 43–53.
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348(19):1875–1883.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Kyle RA, Anderson KC, Geipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF, Jr., Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24(6):929–936.
   PubMed Web of Science ®Google Scholar
• Greidanus J, de Vries EG, Mulder NH, Sleijfer DT, Uges DR, Oosterhuis B, Willemse PH. A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. J Clin Oncol 1989;7(6):790–797.
   PubMed Web of Science ®Google Scholar
• Bensinger WI, Rowley SD, Demirer T, Lilleby K, Schiffman K, Clift RA, Appelbaum FR, Fefer A, Barnett T, Storb R, Chauncey T, Maziarz RT, Klarnet J, McSweeney P, Holmberg L, Maloney DG, Weaver CH, Buckner CD. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 1996;14(5):1447–1456.
   PubMed Web of Science ®Google Scholar
• Vesole DH, Crowley JJ, Catchatourian R, Stiff PJ, Johnson DB, Cromer J, Salmon SE, Barlogie B. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol 1999;17(7):2173–2179.
   PubMed Web of Science ®Google Scholar
• Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003;21(15):2896–2903.
   PubMed Web of Science ®Google Scholar
• Koc Y, Akpek G, Kansu E, Kars A, Tekuzman G, Baltali E, Guler N, Barista I, Gullu I, Ozisik Y, Firat D. Bolus and continuous infusion mitoxantrone in newly diagnosed adult acute lymphoblastic leukemia: results of two consecutive phase II clinical studies. Cancer Invest 1998;16(6):355–365.
   PubMed Web of Science ®Google Scholar
• Smith IE, A'Hern RP, Coombes GA, Howell A, Ebbs SR, Hickish TF, O'Brien ME, Mansi JL, Wilson CB, Robinson AC, Murray PA, Price CG, Perren TJ, Laing RW, Bliss JM. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 2004;15(5):751–758.
   PubMed Web of Science ®Google Scholar
• Larson RA, Daly KM, Choi KE, Han DS, Sinkule JA. A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. J Clin Oncol 1987;5(3):391–397.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Therneau TM, Kyle RA, Greipp PR, Gertz MA. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol 2001;68(4):269–275.
   PubMed Web of Science ®Google Scholar
• Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96(2):133–139.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Frye D, Buzdar AU, Ewer MS, Fraschini G, Hug V, Ames F, Montague E, Carrasco CH, Mackay B, Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 1989;63(1):37–45.
   PubMed Web of Science ®Google Scholar
• Casper ES, Gaynor JJ, Hajdu SI, Magill GB, Tan C, Friedrich C, Brennan MF. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 1991;68(6):1221–1229.
   PubMed Web of Science ®Google Scholar
• Zalupski M, Metch B, Balcerzak S, Fletcher WS, Chapman R, Bonnet JD, Weiss GR, Ryan J, Benjamin RS, Baker LH. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991;83(13):926–932.
   PubMed Web of Science ®Google Scholar